The cost of blood transfusions in cancer patients: A reanalysis of a Canadian economic evaluation

Journal of Oncology Pharmacy Practice

Volumn 6, Issue 2, 2000, Pages 37-42

  Dranitsaris, George ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Blood transfusion; cost analysis

Indexed keywords

EID: 84990397385     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/107815520000600201     Document Type: Article

References (19)

1. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node positive breast cancer. J Clin Oncol. 1998; 16: 2651-2658.
2. Shepherd F, Ramlau R, Mattson K, et al. Randomized study of Taxotere versus best supportive care in nonsmall cell lung cancer patients previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol. 1999; 18; 463a-463a.
3. Slavin S, Nagler E, Naparstek E, Varadi G. Allogeneic nonmyeloablative stem cell transplantation as an emerging new modality for immunotherapy of hematologic malignancies and nonmalignant disorders. Blood. 1998; 92: 520a-520a.
4. Armitage JO. Bone marrow transplantation. New Engl J Med. 1994; 331: 617-628.
5. Estrin JT, Schocket L, Kregenow R, Henry DH. A retrospective review of blood transfusions in cancer patients with anemia. J Hazard Mater. 1999; 4: 318-324.
6. Aledort LM, Mohandas K. Transfusion requirements in patients with malignancy. Semin Oncol. 1996; 33: 6-9.
7. Zucker S. Anemia in cancer. Cancer Invest. 1985; 3: 249-260.
8. Koeller JM, Van Den Berg C. Anemias. In: Young LY, and Koda-Kimble MA, eds. Applied Therapeutics. The Clinical Use of Drugs. Vancouver: Applied Therapeutics Inc.; 1995: 88-1-88-3.
9. Lee GR. The anemia of chronic disease. Semin Hematol. 1983; 20: 61-80.
10. Pavel JN. Red blood cell transfusions for anemia. Semin Oncol Nurs. 1990; 6: 117-122.
11. Ortega A, Dranitsaris G, Puodziunas A. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Tech Assess Health Care. 1998; 14: 788-798.
12. Tretiak R, Laupacis A, Riviere M, et al. Cost of allogenic and autologous blood transfusion in Canada. Can Med Assoc J. 1996; 154: 1501-1508.
13. Ontario Ministry of Health. Schedule of Benefits: Physicians Services Under the Health Insurance Act. Toronto: Ontario Ministry of Health; 1998.
14. Doyle C, Stockler M, Pintilie M, et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol. 1997: 15; 1000-1007.
15. Gresens CJ, Holland PV. Current risks of viral hepatitis from blood transfusions. J Gastroenterol Hepatol. 1998; 13: 443-449.
16. Holland PV. Post-transfusion hepatitis: current risks and causes. Vox Sang. 1998; 2: 135-141.
17. Remis RS, Delage G, Palmer RW. Risk of HIV infection from blood transfusions in Montreal. Can Med Assoc J. 1997; 157: 375-382.
18. Gable CB, Tierce JC, Simison D, et al. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquired Immune Defic Syndr. 1997; 12: 413-420.
19. Ray-Coquard I, Le Cesne A, Rubio MT, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol. 1999; 17: 2840-2846.